Organogenesis (NASDAQ:ORGO) Shares Gap Up – Should You Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO) gapped up prior to trading on Tuesday . The stock had previously closed at $5.42, but opened at $5.56. Organogenesis shares last traded at $5.20, with a volume of 239,503 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upped their price target on Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Price Performance

The firm has a market capitalization of $658.87 million, a price-to-earnings ratio of -86.47 and a beta of 1.66. The company’s fifty day moving average price is $4.09 and its 200 day moving average price is $3.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the sale, the director now directly owns 166,879 shares of the company’s stock, valued at $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 36.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Organogenesis

Institutional investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Organogenesis by 5.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock valued at $1,348,000 after purchasing an additional 24,878 shares during the period. Intech Investment Management LLC acquired a new position in shares of Organogenesis during the third quarter worth approximately $43,000. Charles Schwab Investment Management Inc. boosted its position in shares of Organogenesis by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock worth $2,713,000 after buying an additional 23,675 shares during the period. FMR LLC grew its holdings in Organogenesis by 34.2% in the 3rd quarter. FMR LLC now owns 173,595 shares of the company’s stock worth $496,000 after buying an additional 44,199 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in Organogenesis in the 3rd quarter valued at approximately $36,000. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.